Andreas Rimner
Distinguished in Squamous Cell Lung Carcinoma

Dr. Andreas Rimner

Radiation Oncology
1275 York Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Squamous Cell Lung Carcinoma
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andreas Rimner is a Radiation Oncologist in New York, New York. Dr. Rimner is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Thymectomy.

His clinical research consists of co-authoring 238 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Squamous Cell Lung Carcinoma.

Specialties
Radiation Oncology
Licenses
General Acute Care Hospital in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1275 York Ave, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
Enrollment Status: Recruiting
Publish Date: May 18, 2025
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1
Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer
Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Device
Study Phase: Not Applicable
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Pemetrexed+Cisplatin or carboplatin
Study Phase: Phase 2
Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)
Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Stereotactic Body Radiation Therapy With Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer - A Phase II Single-Arm Trial
Stereotactic Body Radiation Therapy With Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer - A Phase II Single-Arm Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug, Radiation
Study Drug: Durvalumab
Study Phase: Phase 2
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Other
Study Phase: Not Applicable
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug, Other
Study Drugs: Nintedanib, Prednisone
Study Phase: Phase 2
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Pemetrexed, Pemetrexed Disodium
Study Phase: Phase 3
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Radiation, Drug
Study Drug: Olaparib
Study Phase: Phase 1
Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Cisplatin or Carboplatin-Based
Study Phase: Phase 1
An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)
An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug, Radiation
Study Drug: Avelumab
Study Phase: Phase 1/Phase 2
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
View 11 Less Clinical Trials

238 Total Publications

International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors.
International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 05, 2025
Similar Doctors
Distinguished in Squamous Cell Lung Carcinoma
Dr. Benjamin Cooper
Radiation Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Benjamin Cooper
Radiation Oncology

New York University

560 1st Ave, 
New York, NY 
 (1.8 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Cooper is a Radiation Oncologist in New York, New York. Dr. Cooper is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Lung Adenocarcinoma.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Charles B. Simone
Radiation Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Charles B. Simone
Radiation Oncology

Memorial Radiation Oncology Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Simone is a Radiation Oncologist in New York, New York. Dr. Simone is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Jacob Y. Shin
Radiation Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Jacob Y. Shin
Radiation Oncology

Memorial Sloan Kettering Cancer Center At Basking Ridge New Jersey

136 Mountain View Blvd, 
Basking Ridge, NJ 
 (34.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacob Shin is a Radiation Oncologist in Basking Ridge, New Jersey. Dr. Shin is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Cancer, and Large-Cell Lung Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rimner's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile